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At least 30 million people worldwide carry a diagnosis of atrial fibrillation (AF), and many more suffer from undiagnosed, subclinical, or ‘silent’
AF. Atrial fibrillation-related cardiovascular mortality and morbidity, including cardiovascular deaths, heart failure, stroke, and hospitalizations,
remain unacceptably high, even when evidence-based therapies such as anticoagulation and rate control are used. Furthermore, it is still ne-
cessary to define how best to prevent AF, largely due to a lack of clinical measures that would allow identification of treatable causes of AF in any
given patient. Hence, there are important unmet clinical and research needs in the evaluation and management of AF patients. The ensuing
needs and opportunities for improving the quality of AF care were discussed during the fifth Atrial Fibrillation Network/European Heart
Rhythm Association consensus conference in Nice, France, on 22 and 23 January 2015. Here, we report the outcome of this conference,
with a focus on (i) learning from our ‘neighbours’ to improve AF care, (ii) patient-centred approaches to AF management, (iii) structured
care of AF patients, (iv) improving the quality of AF treatment, and (v) personalization of AF management. This report ends with a list of pri-
orities for research in AF patients.
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Keywords Atrial fibrillation † Outcomes † Quality of care † Research † Rate control † Antiarrhythmic drugs † Catheter
ablation † Anticoagulation † Cardiovascular risk † Bleeding † Research priorities
Introduction
At least 30 million people worldwide carry a diagnosis of atrial fib-
rillation (AF),1 and many more suffer from undiagnosed or ‘silent’
AF. Oral anticoagulation can prevent the majority of AF-related
strokes,2 but does only partially mitigate the burden of AF that af-
fects patients, their families, and society3: AF-related cardiovascular
mortality and morbidity, including cardiovascular deaths, heart fail-
ure, stroke, and hospitalizations, remain unacceptably high.3,4 The
prevalence of diagnosed AF has increased in Europe in recent
years,5,6 due to better awareness of AF, earlier and systematic diag-
nosis of AF, and an increase in the conditions that predispose to de-
veloping AF.7 In fact, we have to expect that 2% or even 3% of the
populations in Europe and in other parts of the world suffer from
AF,1,8 including those with silent AF1,8– 10: clearly, this alarming in-
crease calls for better ways to prevent AF: we are not able to pre-
vent AF, largely due to a lack of clinical measures that would allow
identification of treatable causes of AF in any given patient. Hence,
there are important unmet needs in the evaluation and management
of AF patients.
The ensuing needs and opportunities for improving the quality of
AF care were discussed during the fifth Atrial Fibrillation Network
(AFNET)/European Heart Rhythm Association (EHRA) consensus
conference in Nice France, on 22 and 23 January 2015. Here, we re-
port the outcome of this conference, with a focus on (i) learning
from our ‘neighbours’ to improve AF care, (ii) patient-centred ap-
proaches to AF management, (iii) structured care of AF patients,
(iv) improving the quality of AF treatment, and (v) personalization
of AF management. This report ends with a list of priorities for re-
search in AF patients.
Learning from our neighbours
Healthcare systems, like political systems, develop and ‘grow’ into
different shapes in different jurisdictions. Some developments are
well suited for patient-centred care and/or may be more efficient
compared with others. Controlled trials comparing different ways
to deliver AF patient care11,12 and regional differences in AF man-
agement highlight opportunities to improve outcomes in AF
patients.13,14 Systematic comparisons of healthcare systems are a
useful tool to inform change in healthcare systems.15 In addition, in-
formal exchange of healthcare organization can benefit healthcare
professionals and patients. Despite differences in background risk,
complications of AF and treatment strategies, the goals of care re-
main the same: stroke prevention, reduction in cardiovascular com-
plications and amelioration of symptoms. Universally, these issues
can be addressed by thoughtful consideration and administration
of anticoagulant therapy, rate control and rhythm control therapy,
and appropriate management of concomitant cardiovascular
conditions.
Each country has a unique variety of regional or local organiza-
tions that deliver healthcare. In some countries, healthcare plans
(e.g. Medicare in the USA) are in place for some populations but
not for others, whilst in other countries almost universal healthcare
coverage provides equal access to specialist and generalist care (e.g.
Austria, Belgium, Germany, the Netherlands, Scandinavia, the UK,
and others). Private purchase of medications and healthcare ser-
vices is the only means to access healthcare in some other areas
of the world. In some jurisdictions, healthcare is organized centrally
or even directly by state agencies, in others it is managed by regional
authorities or offered by units that compete for patients and pay-
ment. In addition, the care of AF patients differs markedly, as re-
flected by simple indicators such as the responsible healthcare
professional (Table 1).
Observational studies suggest that the prevalence of AF may be
higher in Caucasians than in persons of African or Asian ethnicity.18
Similarly, the differences in stroke risk in patients with diagnosed AF
have been found, e.g. higher stroke rates in China compared with
Europe in patients at similar stroke risk based on scoring sys-
tems.19,20 Such disparity likely reflects the differences in the defin-
ition of cardiovascular diseases, access to diagnostic procedures,
and the differences in the management of cardiovascular diseases in-
cluding antihypertensive treatment, heart failure management, antic-
oagulation,13 or rhythm control interventions.14 The differences in
‘customary’ treatment patterns and different organization of health-
care systems can furthermore explain the variation in the use of
evidence-based AF therapies such as oral anticoagulants,21 in the
quality of the international normalized ration (INR) control or in
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the use of catheter ablation. Such differences are not compatible
with the principle of equal access to evidence-based AF manage-
ment for all patients and may lead to increased cost in the long-term.
In summary, the care offered to AF patients is different in different
countries and regions, at times resulting in variations in quality of
care. There is a huge opportunity to improve AF care by exposing
these differences and identifying the factors that drive high-quality
diagnosis and treatment of AF. International organizations such as
the European Society of Cardiology (ESC) should contribute to
the identification of these differences, and coordinate the discus-
sions that are needed to improve diagnostic and therapeutic path-
ways by learning from our neighbours.
We recommend a continued professional dialogue about the optimal
infrastructure and type of AF care, based on comparable data on type
of AF care, outcomes, and resource use in different healthcare settings
to allow improvement of existing AF services.
We recommend a policy of identifying role models of excellent AF care
for wider implementation.
Patient-centred approaches to
atrial fibrillation management
Shared decision-making with informed
patients
Shared decision-making and active involvement of patients in chron-
ic care is a principle that should guide most relations between pa-
tients and physicians. It seems very suitable for the management
of AF. Recent clinical guidelines have stressed the importance of in-
tegrating patient preferences into AF management.22 – 25 This re-
flects a broader move in society to educate and inform patients
and communities, thus empowering them to contribute actively to
decisions about their care.26 The 2012 ESC AF guidelines have
already emphasized the need for shared decision-making in the man-
agement of AF.23
As stated by Seaburg et al.,27 ‘the goal of shared decision making
[in the management of patients with AF] is to increase the likelihood
that patients will receive the care that they need in a manner consist-
ent with the best available research evidence and their values and
preferences’. It requires a change away from traditional ‘paternalis-
tic’ models of treatment decisions to a model integrating medical
facts into an open discussion with the patient who contributes his
or her own values and preferences. As a result, patients will be ap-
propriately informed about their disease, its potential progression
and complications, and the various treatment options. Atrial fibrilla-
tion seems ideally suited to shared decision-making given the range
of alternative diagnostic and treatment options that are available.
This is particularly true when there is clinical equipoise relating to
a decision affecting the patient in markedly different ways, such as
the choice between antiarrhythmic drugs or catheter ablation for
initial rhythm control of AF. The main aim is to empower the pa-
tients to be appropriately informed about all aspects of their health,
wellness and disease state, ultimately improving the outcome of
care. Active participation of patients is needed to make life style
changes that will improve outcomes and quality of life in AF pa-
tients (Table 2) and to ensure adherence to therapy. However, it
is important to gauge the patient’s desire for their degree of in-
volvement in treatment decisions as some patients may prefer
the doctor to make treatment recommendations while other pre-
fer shared decision-making.28
Patient-reported outcomes
Patient-reported outcomes (PRO) are defined as ‘any report of
the status of a patient’s health condition that comes directly from
the patient, without interpretation of the patient’s response by a
clinician or anyone else’.29 Patient-reported outcomes include as-
sessment of health-related quality of life and symptoms. Patient-
reported outcomes may be used in a number of applications30 to
provide the patient voice within AF care. In a routine clinical setting,
quality of life or symptom questionnaires may be used to provide a
standardized estimation of a patient’s well-being to healthcare
providers. Although most instruments have been validated as
paper questionnaires, completed by the patient or with the
help of a healthcare professional, they are suitable for digital,
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Examples of existing care models for the care of AF patients
Care model Advantages Disadvantages
General practitioner Easy access for patients; possibility to perform initial tests
(history, ECG, blood sample)
Limited initial evaluation; limited management
options; lower adherence to guidelines16
Cardiologist/AF subspecialist Experience; comprehensive evaluation; full range of
treatment options
Resource demanding; initially expensive
Integrated care of general practitioner and
internal medicine specialist
More complete assessment and management of
co-morbidities
Limited cardiology-specific evaluation and
management options
Integrated care of general practitioner and
cardiologist
More tailored management approach using full range of
treatment options; distribution of care across
healthcare system
Limited cardiology-specific follow-up
Cardiologist led integrated care including
nurses, allied professionals/lifestyle
specialists
Full assessment and range of treatments; tailored
follow-up; structured care
Costs (but possibly cost-effective)
Nurse led integrated care Patient-centred care approach; efficient and possibly
cost-effective17
Education, training, and monitoring of staff
A roadmap to improve the quality of AF management 39
Downloaded from https://academic.oup.com/europace/article-abstract/18/1/37/2398833
by Belgrade University user
on 13 March 2018
semi-automated, or remote assessment of patients.31 In the future,
these data may be used at an individual level to identify patients with
deteriorating symptoms or aggregated to provide a quality measure.
Although the use of PRO instruments in AF patients is in its infancy,
these data are likely to evolve further and may develop into a quality
measure in the future.32– 34
Shared decision-making in the care of
atrial fibrillation patients
Once AF is diagnosed, individual assessment should identify the
modifiable risk factors (e.g. arterial hypertension, diabetes mellitus,
alcohol consumption, obesity, smoking, sleep apnoea, and concomi-
tant cardiovascular diseases) which are found in 60% of popula-
tions with AF.35 Such precipitating factors may be modified by
changes in lifestyle,36,37 while an inherited predisposition to AF can-
not be modified. Since AF is a heterogeneous disease with respect
to its aetiology, pathophysiology, mechanisms, clinical presentation,
natural history,38,39 and outcomes, patients are entitled to compre-
hensive information on the causes, manifestations, and complica-
tions of AF. The concept of different types of AF reflecting the
main pathophysiological drivers of the arrhythmia seems suitable
for this conversation7 and needs to be supplemented by information
on the complex interaction of disease-related factors in the shared
decision-making process. Patients with AF need adequate and
understandable information about the main complications, such as
stroke, cognitive impairment, heart failure, and sudden death.
They should recognize signs of stroke (new-onset neurological def-
icit) and heart failure (shortness of breath) and the need for imme-
diate medical attention when such symptoms develop or quickly
worsen. Information technology can provide such information in a
tailored way via interactive electronic educational material (e.g.
www.afibmatters.org or http://www.atrial-fibrillation-network.eu/
en/home or www.afassociation.org.uk). This will require time and
a willingness to explain the information in a language that the patient
understands. These resources seem well invested to enable the
patient to understand and execute the agreed management plan.
We recommend the involvement of all AF patients in the major deci-
sions about their care, and to enhance the publicly available information
on AF, its complications, and the therapeutic options.
Structured care of atrial
fibrillation patients
Evidence-based management of atrial
fibrillation patients
Many aspects of AF management are informed by clear evidence,
which is reflected in largely overlapping (but with some worrying dif-
ferences) international guidelines on treatment of underlying cardio-
vascular conditions, anticoagulation, rate control, and rhythm
control.22,23 There are not only multiple treatment modalities, but
also many causes of AF, drivers of AF-related complications, and rea-
sons for impaired patient well-being. The profile and treatment needs
of AF patients change over time, and frequently require in-patient hos-
pital care when managed in current approaches.40,41 Hence, adequate
management of AF patients is complex. It requires a structured ap-
proach.11,42 Such AF care should ensure that evidence-based therapy
is offered to all AF patients, and that follow-up and repeated evalu-
ation are sufficient to maintain adherence to agreed management
principles. Integrated, multidisciplinary care of AF patients, supported
by information technology and patient education, can help to avoid
AF-related complications and hospital stays according to recent ran-
domized trials, thereby reducing the burden of AF to patients and de-
creasing the cost of care.43 The organization of care will differ locally
(see ‘Learning from our neighbours’ section) and local solutions will
need to be developed to define a good model of care.
We suggest the development of structured, patient-centred care plans
for all AF patients, based on structured initial evaluation and guided by risk
profiling and symptom assessment (Tables 2 and 3).42 Interdisciplinary,
dedicated AF services which also incorporate lifestyle interventions are like-
ly to facilitate such a structured, risk-based, patient-centred care model.43
We recommend the development of integrated and structured approaches
to AF care led by interdisciplinary teams to improve the quality of AF care
(Figure 1).
Improving the quality of atrial
fibrillation treatment
Patients are entitled to high-quality care that is safe, effective, and ac-
cessible. While the medical literature has traditionally focused on the
best way of caring for patients, it is important to define minimal stan-
dards of good care for AF patients. Such standards would ideally be
developed and endorsed with wide input from global stakeholders.
We recommend that quality standards are defined and monitored in AF
care. EHRA, AFNET, and similar organizations in other parts of the world
should play a central role in the further definition and dissemination of
such criteria, and in linking these to outcomes. The following sections
(‘Timely diagnosis of atrial fibrillation’, ‘Defining and improving the quality
of stroke prevention’, ‘What is effective rate control?’, and ‘Improving qual-
ity of rhythm control therapy’) outline quality criteria, which are summar-
ized in Tables 4–6.
Timely diagnosis of atrial fibrillation
Many people, especially those who are older and have concomi-
tant cardiovascular conditions, suffer from undiagnosed, ‘silent’
AF. The prognosis of untreated asymptomatic AF is characterized
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Life style changes that can improve AF
management by either improving outcomes, reducing
the risk of complications, rendering recurrent AF less
likely, or improving quality of life
Life style change Effect on
Outcomes and
complications
Recurrent AF
and quality of life
Regular physical
activity
X Not known
Weight reduction Not known X
Low sodium, low fat diet X (by reducing blood
pressure)
Not known
Smoking cessation X Not known
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by a high risk of stroke and death which can be reduced by appro-
priate oral anticoagulation.53 Screening for unknown AF and initi-
ation of anticoagulation has the potential to prevent strokes in
patients with undiagnosed AF, but has so far mainly been evaluated
in physician offices, where pulse palpation followed by 12-lead
electrocardiogram (ECG) recording seems cost-effective for AF
screening.23,54 A recent systematic review55 demonstrated that
unknown AF would be detected in 1.4% of the population aged
≥65 on a single screening whether in a clinical or community set-
ting. Pulse palpation is universally available to an educated popula-
tion. Novel technologies, which allow easy cardiac rhythm
assessment by lay persons and patients, either by pulse irregularity
(oscillometry56 or smart phone camera57) or by analysis of an ECG
rhythm strip,58 – 61 are now readily available and offer better, less
costly methods for more effective and more broadly based AF
screening. A number of studies have explored population or
clinic screening using hand-held single-lead ECG devices.58 – 60
An economic analysis showed that if an AF screen with these de-
vices at a single time point was extended to the population aged
65–84 years, it would be cost-effective for stroke prevention.59,62
Community pilot screening studies suggest that the criteria for
widespread screening over age 65 are now met,63 but the precise
implementation method would need to fit with the country-
specific healthcare system.
Silent AF first presenting with ischaemic stroke accounts for at
least 10% of all ischaemic strokes,64 – 67 and widespread screening
could substantially reduce this figure. A systematic review found
that an additional 11.5% of survivors will have paroxysmal AF
which remains undetected by current ECG monitoring practices,
but may be detected by prolonged non-invasive or invasive ECG
monitoring, although the available studies are heterogeneous.68
More recently, two randomized trials of either 30-day external
monitors10 or 1–3 years of implantable cardiac monitors69 de-
monstrated an even higher detection rate of AF, albeit in a sub-
group of stroke survivors with ‘cryptogenic’ stroke. Some form
of prolonged monitoring after ischaemic stroke should now be-
come the standard of care,70 and offered by a high-quality AF ser-
vice. Ongoing randomized multicentre studies such as MonDAFIS
(NCT02204267) will determine whether the detection of ‘silent’
Table 3 Structured initial care of AF patients
A. Components of initial care
ECG—confirmation of AF22
Detailed medical history
mEHRA symptom assessment44
CHA2DS2-VASc stroke risk assessment
45
Assessment and correction of modifiable bleeding risk factors (e.g.
by HASBLED score)46
Physical examination including blood pressure and body mass index
Risk factors and comorbidities assessment—including heart failure,
chronic airways disease, dementia, sleep apnoea, renal disease,
diabetes, thyroid disease, and coronary artery disease—require
cardiac imaging (usually echocardiogram) and blood sampling24
B. Tailored additional evaluation according to the patient
Additional diagnostic tests
Correction of risk factors
C. Initial management plan
According to ESC guidelines
Defined by an AF team representing all relevant expertize
Advice on life style changes affecting outcomes and AF
D. Follow-up
Regular, scheduled follow-ups according to the model of care
(see Table 1)
Assessment of symptoms and PRO (see ‘Patient-centred
approaches to atrial fibrillation management’ section and
Supplementary material online, Table S1)
Heart rate targets (see ‘Improving the quality of AF treatment’ section)
Adherence and response to treatment
Complications of treatment and complications of AF
Assessment of quality metric targets (see Tables 4–6 and
Supplementary material online, Table S1)
Informed decision on adjustment of therapy
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Figure 1 Roadmap to improve quality of AF services. Shown is a virtuous circle relying on four major pillars to improve the quality of AF services
for patients. Shared decision-making, quantifiable quality measures, integration of AF services across healthcare sectors, and the use of stratified
approaches to therapy can improve AF service quality. They will require continuous evaluation of quality.
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AF after acute ischemic stroke will change long-term management
in stroke survivors.
We recommend the establishment of more widespread screening
programmes for persistent and paroxysmal AF in those over age 65,
and in populations at risk, particularly survivors of ischaemic stroke.
Defining and improving the quality of
stroke prevention
The majority of ischaemic strokes in AF patients is caused by AF, and
a substantial proportion of those ‘cardio-embolic’ strokes can be
prevented by oral anticoagulation. Aspirin is not effective in prevent-
ing strokes in AF. Nonetheless, underuse or premature termination
of therapy with oral anticoagulants is still common.71 – 76 Although
non-vitamin K antagonist (VKA) oral anticoagulants (NOACs) are
easy to handle and offer the promise of improved efficacy and safety
compared with VKA treatment,2,77 there is still a substantial
underuse of oral anticoagulation in AF patients in the ‘NOAC
era’.78,79 While anticoagulation therapy needs to be paused when pa-
tients actively bleed, absolute contraindications to long-term anti-
coagulant treatment in AF patients are rare, e.g. severe bleeding
without treatable underlying cause in critical organs. The bleeding risk
of anticoagulant use in elderly patients, in patients with cognitive dys-
function, or in those with frequent falls or frailty is often overesti-
mated and should usually not preclude the use of anticoagulants.80,81
Oral anticoagulants need to be taken consistently. The best
evidence for this stems from analyses of the time of patients treated
with VKA within and below the therapeutic range,82 but it seems rea-
sonable to suggest that regular intake of relatively short half-life
NOACs is even more important for successful stroke preven-
tion.76,83,84 Although adherence to therapy is currently not measured
systematically in clinical practice, the outcomes of recent observation-
al datasets replicate the findings in Phase III trials of NOACs.77,85,86
Dedicated interventions to enhance adherence to therapy are
Table 5 Quality criteria for rhythm control therapy in
AF patients
Individual assessment
Quantify AF-related symptoms (mEHRA score)52
Assess the need for rhythm control on the background of adequate
rate control
Assess concomitant cardiovascular diseases and prior attempts of
rhythm control to inform choice of AAD
Assess 12-lead ECG for signs of conduction or repolarization
disturbances
Document baseline QT interval, QTc, QRS duration, and QRS
abnormalities
Check baseline blood levels as needed (thyroid and liver function for
amiodarone, liver function and creatinine for dronedarone,
creatinine and estimated creatinine clearance for sotalol,
flecainide, and propafenone)
Guideline adherent prescription and therapy initiation
Choose antiarrhythmic drug according to ESC guidelines
Prescribe effective dose
Monitor ECG during therapy initiation (days 1–3 for flecainide,
propafenone, and sotalol; weeks 1 and 2 for dronedarone; weeks
1 and 4 for amiodarone)
Monitor blood levels as needed
Dedicated patient education48
Provide information on:
The main aims of rhythm control therapy (reducing symptoms)
The possible need for further procedures (cardioversion,
catheter ablation)
Possible side effects including proarrhythmia
All information tailored to the patient’s ability to understand and
desire for information
Once antiarrhythmic drug treatment decision is made
Provide clear information on duration of therapy (pill in the pocket,
short-term, long-term) and drug interactions (e.g. anticoagulants)
Check patient understanding of key elements: dose, frequency, with/
without food, result of non-adherence (recurrence of AF)
Provide written information to reinforce verbal information
Table 4 Quality criteria for management components
of AF (quality criteria for anticoagulant therapy)
Individual risk assessment
Assess stroke risk with CHA2DS2-VASc score
Assess bleeding risk and minimize bleeding risk factors
Control blood pressure
Discontinue treatment with non-essential antiplatelet(s)/NSAIDs
Counsel patient to reduce alcohol consumption if excessive
Check renal function and estimate creatinine clearance prior to
deciding on anticoagulation therapy
Guideline adherent OAC prescription following documentation of
stroke risk factors (e.g. by CHA2DS2VASc score)
If patient is on VKA, achieve high time in therapeutic range (TTR,
e.g. .65%)
Decision-making
Individualized approach to decision-making
Gauge and follow patient’s desire for involvement in making OAC
treatment decision (e.g. following input from patient, doctor, or
relative)
Support of anticoagulation therapy
OAC-specific information (verbally, pictorially, and written)11,51
Check patient understanding of key elements: dose, frequency, with/
without food, bleeding side effects; result of non-adherence
(stroke)
Check and reinforce knowledge on transient ischemic attack or
stroke alarm symptoms, e.g. by ‘FAST’ (face, arm, speech, time)
and explain need for emergency transfer to stroke unit when such
symptoms occur
Provide written information to reinforce verbal information
All information tailored to the patient’s ability to understand and
desire for information
Providers of care (see Tables 2 and 3, one option should be available)
Physician, nurse, pharmacist, other healthcare professional, ‘expert’
patient, and combination
Nurse led supported by consultant expertize11
Supported with software to aid clinical decisions (algorithms)49
Intervention for VKA initiation50
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currently being evaluated, e.g. AEGEAN (NCT01184350).87,88
Permanent withdrawal of anticoagulation therapy is associated with
cardiovascular complications. Re-initiation of anticoagulation after a
bleeding event is often possible and clinically justified. Difficult deci-
sions, including the discontinuation of anticoagulation, should be ta-
ken by multidisciplinary teams involving AF, anticoagulation, stroke
specialists, as well as the patients to adequately balance the risks
and benefits of continued anticoagulation.
Limited reimbursement of NOACs is an important driver of in-
equality in care of patients with AF.79 This group advocates access
to NOACs for all AF patients in need for oral anticoagulation as
an initial therapy option.77,85,89,90 When this is not deemed feasible,
clinical estimates for the likelihood to achieve good anticoagulation
with VKA could be considered to identify patients who can be trea-
ted with VKA.85,91
We recommend the following steps to improve stroke prevention in AF
patients:
(1) All AF patients in need of oral anticoagulation should have access to
NOAC therapy, or to VKA therapy, if NOACs therapy is not feasible.
(2) We recommend a structured follow-up for all anticoagulated AF
patients to remind the patient of the need for AF treatment and to
increase adherence and persistence to therapy.11,92,93
(3) Atrial fibrillation patients who suffer a stroke should be acutely
managed in specialized stroke units.94
What is effective rate control?
The goal of rate control therapy of AF is to reduce patient symp-
toms and prevent a tachycardia-related reduction in myocardial
function. While these treatment goals can be achieved with a lenient
rate control approach in some patients,95 others may require stric-
ter rate control, such as those with heart failure or persistent symp-
toms.23,24 The effectiveness of rate control therapy should be
assessed at regular intervals in AF patients as part of integrated
AF management. Adjustments to rate control medication seem ne-
cessary in many patients,71,96 and all AF patients need systematic
follow-up to allow such adjustments over time. Such assessment
will require analysis of a conventional 12-lead ECG, Holter consid-
eration of patient symptoms and preferences, and repeated assess-
ment of left ventricular function (especially when symptoms
worsen). The optimal therapy for achieving rate control requires
further research.97,98 Until the results of such research are available,
it will be difficult to define quality indicators for effective rate con-
trol therapy in addition to the simple statement that resting heart
rate should be ,110 b.p.m. In patients who remain symptomatic
on such a lenient rate control therapy, it may be worthwhile to con-
trol rate during exercise, and/or to aim for a lower resting heart rate.
Improving quality of rhythm control
therapy
Defining quality in atrial fibrillation ablation
The evidence underpinning the use of catheter ablation to maintain
sinus rhythm in symptomatic AF patients has mainly been generated
in recognized regional, national, or international centres of electro-
physiological excellence. As AF ablation is being offered to more pa-
tients, and hence AF ablation services are established in more and
more centres, recruiting and training of electrophysiologists and
maintaining a high quality of AF ablation procedures develops into
a key issue. It is recognized that there is a need to define and mea-
sure quality, both in terms of AF ablation operators and institutions
offering AF ablation. Catheter ablation of AF, especially isolation of
the pulmonary veins, is now a standardized procedure that has be-
come part of routine clinical care.24,26,47 Thus, a set of variables to
define both a qualified operator and a quality AF ablation centre is
proposed (Table 6). Using these criteria, systematic assessment of
the AF ablation operators and of the AF ablation centres can be
undertaken to ensure their quality, and to study the validity and
the clinical usefulness of these criteria. This process should be led
by professional organizations such as EHRA or Heart Rhythm
Society.
Hybrid rhythm control therapy
It is well recognized that catheter ablation will not completely
eliminate AF in many patients.99,100 It is in this context that we
discuss the concept of ‘hybrid therapy’ for AF (ablation plus anti-
arrhythmic drugs). Hybrid therapy, defined as the use of antiar-
rhythmic drug therapy more than 3 months following an ablation
to reduce symptoms and/or episodes of AF, is a common thera-
peutic concept in AF patients.101,102,103 While it is common prac-
tice to stop antiarrhythmic drugs a few weeks or months after
Table 6 Quality indicators for AF ablation47
A. Quality indicators for care in AF ablation centres
Structured and documented assessment of indications for AF
ablation
Symptoms (mEHRA score) Prior rhythm control attempts
Other therapeutic options (antiarrhythmic drugs, no further
rhythm control therapy, combination therapy)
Likelihood of recurrent AF
Required infrastructure for AF ablation centres in addition to the
general quality criteria (see Tables 4 and 5)
Dedicated, adequately equipped electrophysiology laboratory
Minimum number of AF ablation procedures per year (over 50)
Availability of backup open heart surgery capable of managing
complications of AF ablation, especially pericardial tamponade
Availability of backup anaesthetic support
Database to track complications over time
Regular structured complication conference
Standardized patient follow-up programme
B. Quality indicators for AF ablation operators
Adequately trained and qualified electrophysiologists
Operators should perform a minimum of 25 AF ablation procedures
per year
Rate of major complications: defined as complications that prolong
hospital stay or require intervention. The rate of cardiac
tamponade is an important subset of the complication rate that
should be separately monitored
Although efficacy is also important, this parameter is difficult to
define as it depends on the type and complexity of the patient’s
AF, the extent of post-ablation monitoring, the definition of
success, and the duration of follow-up. We encourage operators
to track the recurrence rate of AF, rate of re-ablation, and to
assess quality of life before and after ablation using dedicated PRO
instruments
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restoration of sinus rhythm by catheter ablation104 or cardiover-
sion,105 the result is an excess in AF recurrences compared with con-
tinued antiarrhythmic drug therapy.104,105 Hence, some patients may be
advised and/or may prefer to continue antiarrhythmic drug therapy after
ablation of AF, especially when the therapy is well tolerated, integrating
patient preferences, the perceived risk of recurrence, and the risk of
therapy.106
Repeat ablation or antiarrhythmic drug therapy after atrial
fibrillation ablation?
Many patients who undergo an initial AF ablation will continue to
experience symptomatic AF once antiarrhythmic drugs have been
discontinued.47,101 Decisions to perform a repeat ablation should
only be done once recurrence of AF has been documented and fol-
low the same process used to decide on the initial AF ablation. This
process involves shared decision-making based on a consideration
of safety and efficacy of repeat ablation, discussion of all treatment
options including antiarrhythmic drug therapy and acceptance of AF
(‘rate control only’), and should integrate patient preferences. Here-
by, the patient has a better appreciation of what the procedure in-
volves, and the electrophysiologist has more knowledge about the
procedural details, including risk and the potential extent of re-
ablation. Atrial tachycardias may be better amenable to re-ablation
than AF. Some patients will prefer a trial of antiarrhythmic drugs
rather than repeat ablation.
We recommend systematic collection of information on centre and op-
erator quality, based on simple quality indicators and procedural compli-
cations (Table 6), from all AF ablation centres.
We recommend further research into the best rhythm control therapy
in patients with recurrent AF after AF ablation.
Beyond the present state of the art:
personalized atrial fibrillation
management
A broad range of different cellular and molecular mechanisms
underlie AF and are modified by environmental factors.107 – 109
Thus, the manifestation, progression, and outcome of disease will
vary between these subtypes of AF, consistent with clinical observa-
tions.7 Furthermore, the clinical differentiation between ‘paroxys-
mal’ and ‘persistent’ AF may be poor, suggesting that this
differentiation is not reflecting different biology.110 Clinical condi-
tions that are associated with AF and AF-related complications
may vary substantially by AF aetiology, but will overlap. To investi-
gate the development of mechanism-oriented therapy of AF, prior
consensus conferences suggested a pathophysiological classification
of AF types.7 The precise identification of AF mechanisms would
ideally involve assessment of atrial tissue. As this is inherently diffi-
cult to obtain, blood (or possibly imaging) markers that correlate
with atrial pathophysiology could indicate whether major molecular
mechanisms of AF are present in a given patient. Cardiac imaging
modalities such as echocardiography, CT, or magnetic resonance
imaging give a relatively detailed view of atrial size and to some ex-
tent of atrial structure. They usually require specialized equipment
and expertize for interpretation, and have been discussed in a recent
review.7 The existing biomarkers for AF were therefore reviewed
with a view to utilising them for the classification of AF patients
into different types (Figure 1).
Unfortunately, many biomarkers that have been evaluated in AF
patients identify abnormal cardiac or inflammatory states, rather
than reflecting atrial pathology.
Natriuretic peptides, in particular B-type natriuretic peptide (BNP),
cannot differentiate between underlying or concomitant cardiovas-
cular conditions and comorbidities. Elevated BNP is associated with
incident AF, and BNP is correlated with disease burden, e.g. fre-
quency and duration of AF episodes and overall cardiac abnormal-
ity.11 Its predictive ability for new-onset AF in community cohorts is
strong, but improvement in C-statistic and reclassification remains
modest.112,113 N-terminal pro-BNP is also strongly and independ-
ently associated with stroke and mortality in patients with AF.114
C-reactive protein may be considered for general cardiovascular
risk assessment when treatment decisions based on conventional
risk scoring are uncertain.115 Although modification of C-reactive
protein concentrations, e.g. by statin treatment may alter AF
risk,116 Mendelian randomization, i.e. a correlation of genetic deter-
minants of CRP levels and their association with AF, suggests that it
is unlikely that C-reactive protein per se causes AF.117 Consequently,
the power of CRP to identify patients with AF is low.112,113
Similarly, markers of impaired kidney and bone marrow func-
tion such as glomerular filtration rate, cystatin C, or low haemoglobin
have been associated with many aspects of AF pathophysi-
ology.118,119 They represent aging, general health status and co-
morbid conditions that affect AF incidence and prognosis rather
than intrinsic AF mechanisms. While the combination of these
markers of disease can slightly improve the prediction of incident
AF,112,113 or complications of therapy (e.g. bleeding on anticoagu-
lants), the value of such general biomarkers for personalized man-
agement of AF needs to be established. It seems unlikely that
these markers can discriminate different subtypes of AF in the
near future (Figure 2).
Common genetic variants
Genetic variation is fairly stable over a life course, independent of
environmental changes and may help to define AF subtypes. In
rare monogenic AF, a single mutation determines the disease
phenotype (e.g. long-QT syndrome or an inherited cardiomyopathy,
but also in familial AF120,121). Common genetic polymorphisms cor-
relate with the risk of AF development and risk of stroke, and pre-
dispose to recurrences of AF on antiarrhythmic drugs122 or ablation
success.123 About a third of all AF patients carry common gene var-
iants that predispose to AF.124,125 In general, every single nucleotide
polymorphism (SNP) only carries a small relative risk, but they can
be combined to generate more precise information.125,126 Genetic-
ally determined subtypes of AF in the community have not yet been
formulated. Future in-depth analysis of genetic information col-
lected in large consortia will provide additional information on the
genetic underpinnings of AF, including very many SNPs. Further-
more, the molecular mechanisms conveying AF risk in carriers of
the AF-related genetic variants may unveil novel ‘atrial specific’ dis-
ease pathways and biomarkers, including altered epigenetic- or
microRNA-related pathways.127 – 132 The practical consequences
of these findings need to be determined and tested in controlled
trials.
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The search for atrial-specific biomarkers
The increasingly broad availability of novel ‘big data’ technologies
will provide access to blood and tissue for largely unbiased ‘omics’
interrogation. Omics data including genome transcriptome, prote-
ome, and metabolome information will reveal intermediate pheno-
types and disease patterns in AF. These analyses have the potential
to identify promising new AF biomarkers. The information derived
from different clinical and molecular sources then needs to be com-
bined to identify new biomarkers or marker signatures of clinical
relevance.133
Novel biomarkers will need to be able to identify a group of AF
patients (or populations at risk for AF) who respond well to a given
therapy and/or who show a distinct course of disease, e.g. in terms
of AF progression or for complications of AF. Subsequently, proof of
concept and prospective controlled testing need to demonstrate
feasibility and cost-effectiveness.
The overall success of future biomarker studies will rely crucially
on two interrelated issues: the establishment of distinct AF pheno-
types and rigorous validation of biomarkers, e.g. as recently sug-
gested by the Transparent Reporting of a multivariable prediction
model for Individual Prognosis Or Diagnosis (TRIPOD) investiga-
tors.134 Current biomarker studies are limited by the crude AF
phenotype definition that impairs specific associations. On the
other hand, biomarkers and biomarker signatures may largely en-
hance the differentiation of AF subtypes and their optimal manage-
ment. Existing and emerging biomarkers and AF subtypes will then
need rigorous validation and prospective testing.
Electrocardiogram parameters
The ECG is a widely available diagnostic test in many healthcare set-
tings. Furthermore, emerging technology will give patients and citi-
zens unsupervised access to ECG recordings. Several ECG
parameters can be used to detect patients at risk for AF. The PR
interval has a clear genetic trait135,136 and a prolonged PR interval
is associated with an increased the risk of prevalent AF in popula-
tions.137 – 139 Direct electrocardiographic contact mapping studies
in patients undergoing open-chest surgery have indeed demon-
strated that a progressive structural remodelling process is reflected
in more complex atrial activation patterns,140,141 which may pro-
mote recurrent AF.142– 144 The complexity of the AF activation pat-
tern may be indirectly measured by time domain (F-wave analysis,
principal component analysis, and sample entropy) and frequency
domain (dominant frequency, organization index of power spec-
trum, and spectral entropy) parameters.145 Such quantifiable para-
meters of ‘AF complexity’ have been evaluated as markers for
recurrent AF in patients receiving rhythm control therapy (cardio-
version, antiarrhythmic drug therapy, or catheter ablation).146,147
Sufficiently powered studies using standardized technology are
needed to determine the clinical value of ECG analyses during AF
to differentiate different types of AF.146
We recommend performing properly powered genomic, genetic, and
biochemical analyses in controlled trials.
We recommend using existing large biosample collections to identify
atrial-specific biomarkers.
We recommend research into clinical parameters that can differentiate
different ‘aetiologic types’ of AF.
Research priorities in the next
5 years
Based on the challenges in understanding and eliminating the in-
equalities and barriers that prevent optimal care of AF described
above, we have outlined the priority research needs:
(1) Prospective studies evaluating the prognostic value of modern
rhythm control therapy are fortunately underway and should
be completed as soon as possible.
(2) Prospective studies are needed to determine the most effect-
ive strategy for AF detection in populations and in patients at
ECG
Substrate Triggers
Validation
Va
lid
at
ion
Complications/Outcome
Underlying disease
Response to therapy
AF subtype
Biomarkers
Clinical presentation
Figure 2 Biomarkers may help to define AF subtypes. They can comprise blood- and tissue-based markers as well as electrocardiographic or
further objectively determined characteristics (e.g. atrial imaging). Both, biomarkers and existing and novel AF phenotypes need rigorous
validation.
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risk for AF and stroke, including the methods of detection,
implementation and cost-effectiveness.
(3) Evaluation of integrated and structured care approaches com-
pared with current care models has immense potential to im-
prove quality of AF patient care and is essential to make these
useful in clinical practice.
(4) Definition of the optimal PRO to capture AF-related symp-
toms and patients’ experiences of AF, and the development
and adoption of methods to ensure optimal PRO assessment
and reporting from AF trials.
(5) Evaluation of new parameters (e.g. blood biomarkers, ECG
parameters, etc.) to refine anticoagulation decisions in patients
with an intermediate or low risk for stroke.
(6) Strategies to minimize interruption or discontinuation of anti-
coagulant therapy should be systematically evaluated, including
different in-person or remote follow-up patterns and inter-
ventions geared at empowering patients.
(7) Interdisciplinary therapeutic strategies for ‘therapy failures’ on
oral anticoagulation, e.g. patients with an ischaemic stroke on
adequate anticoagulation or those with severe bleeds, should
be developed and evaluated.
(8) Controlled trials of anticoagulation strategies in AF patients
with advanced kidney disease (modification of diet in renal dis-
ease study Stages IV–V) are urgently needed.
(9) We recommend high-quality research projects on the re-
search on timing of recommencing oral anticoagulants after
bleeding.148
(10) The best use of left atrial appendage occlusion devices in clin-
ical practice is not well established.149,150 Evaluation of this
technology in patient groups with the potentially highest bene-
fit and optimization of post-interventional antithrombotic
treatment is needed.
(11) Controlled studies on heart rate control comparing beta
adrenoceptor-blockers, digoxin, and non-dihydropyridine cal-
cium channel blockers as well as heart rate targets and their
effects on quality of life, cardiac function, and cardiovascular
outcomes are urgently needed.
(12) Prospective studies evaluating the success of hybrid rhythm
control therapy combining antiarrhythmic drugs and ablation
compared with catheter ablation alone seem warranted.
Follow-up after catheter ablation for AF should be standar-
dized to enable comparison of research results. Evaluation
of novel markers for different ‘types’ of AF should be inte-
grated into such projects.
(13) Databases of existing trials and cohort studies should be used
to propose clinical subtypes of AF, e.g. based on imaging, ECG
or on blood biomarkers (including genetic markers).
(14) Genetic risk variants or genetic risk scores for AF should be
examined to see if they can help to identify AF or stroke risk
prediction, the subtypes of AF, response to therapies, or clin-
ical outcomes.
(15) Since clinical trials of AF represent unique research opportun-
ities, we encourage the systematic collection of AF covariate
data and samples to enable future studies on biomarkers and
‘types of AF’.
(16) Patients should be actively involved in clinical AF research pro-
jects. Patients can for example advise on patient information
sheets, lay summaries and consent forms and help to optimize
recruitment strategies, but also contribute to practical design
aspects.151 To ensure effective patient involvement, all par-
ties should be clear of the role of patient involvement.
More information can be found (http://www.nets.nihr.ac.uk/ppi;
and http://www.invo.org.uk/).
(17) Mechanistic research should be conducted to link genetic var-
iants to AF mechanisms, and to reveal novel therapeutic
targets.
(18) Long-term research funding is critically necessary to address
each of these challenges and to ensure the optimal treatment
of AF.
Supplementary material
Supplementary material is available at Europace online.
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